Clinical Trials Logo

Clinical Trial Summary

Respiratory Syncytial Virus (RSV) is a leading cause of childhood illness and hospitalization across the world. In addition to acute mortality and morbidity, RSV infection is associated with developing recurrent wheeze in pre-school children and asthma in later life. The overarching aim of the study is to demonstrate the long-term effect of RSV infection on child health in resource-poor settings.

Children previously infected with RSV in their first two months of life and age-matched controls will be followed and epidemiological data will be compared in terms of prevalence of asthma, lung function status, physical growth status, and asthma risk factors. Enrolled children will be routinely assessed for a period of 12 months. During this period, this study will record the health status of the children (respiratory tract illness, wheeze, cough, other illness, and attendance at medical services), physical growth (height, weight and mid-upper arm circumference), family history of atopic diseases (e.g. asthma) and environmental risk exposure (indoor tobacco smoke, crowding, and cooking fuels, cooking place) among enrolled children. Where the acute asthma exacerbation will be suspected, physicians will assess the lung condition of the enrolled sick children using stethoscope and peak flow-meter. The lung function of children will be measured using spirometry, hyper-reactivity against common allergens will be performed using skin prick methods, exercise challenge test will be performed to understand the airway hyperresponsiveness, and blood eosinophil count determine the eosinophil level in the peripheral blood.


Clinical Trial Description

Background: Respiratory syncytial virus (RSV) is the most common cause of childhood illness which attack the lower respiratory tract and develop bronchitis and pneumonia. Approximately 70% of infants are infected with RSV during their first year of life, and almost all children are infected at least once by 2 years of age (Wu & Hartert, 2011).

Each year, an estimated 33·1 million episodes of RSV-associated acute lower respiratory infections occur among under-five children globally, leading to 3·2 million hospitalizations and 118,200 deaths (Ting Shi & Acacio, 2017). The burden of RSV-associated severe acute lower respiratory tract infection is 10 times higher in developing countries compared to that in developed countries (36.1 per 1000 life birth vs 3.2 per 1000 life birth, respectively).

In addition to acute mortality and morbidity, RSV infection has a long-term effect on children's health (Jat & Kabra, 2017; Kneyber, Steyerberg, de Groot, & Moll, 2000). RSV infection can induce a state of bronchial hyper-reactivity that has an association with the development of asthma in later life (Balfour-Lynn, 1996), which, in turn, is a major risk factor of chronic obstructive pulmonary disease in adulthood (Svanes et al., 2010).. The prevalence of wheezing and asthma were reported two times higher in the children who had RSV bronchitis in infancy compared with children without a history of bronchiolitis during infancy (Sigurs et al., 2010). In a report, it was shown that among the children who experienced asthma by school age, 31% of them had healthcare visits in infancy due to respiratory diseases (Wu & Hartert, 2011). The severity of the RSV associated illness was reported as an additive factor for asthma risk. Hartert et, al., reported that asthma prevalence was two times higher in the infants who were hospitalized for RSV infection compared to the other who received care at the outdoor department (Wu & Hartert, 2011). In the mouse model, it was found that viral infection in neonatal rats delayed the growth of secondary septa, decreased the alveolar surface density by 14 to 26%, and reduced the diameter of terminal bronchioles by 11 and 20% (Castleman, Sorkness, Lemanske, Grasee, & Suyemoto, 1988). However, there is no data on the effect of RSV infection on the lung of neonates. In human, the lung remains premature at birth and continue to develop for 2-3 years postnatally and can be assumed that the impact of RSV infection during early infancy would be very severe.

Collecting clinical samples from young infants and lack of appropriate diagnostic to detect RSV virus are the major obstacles to study RSV infection in developing countries. No study from developing countries has investigated the long-term effect of RSV infections incurred during the young infant period. It is assumed that the long-term effect of RSV infection might be more intense if infection occurs during this period, as the lungs of newborns continue to develop for the first several months of life.

Recently, a study aimed to determine the etiology of young infant infection at five centers of three South Asian countries (Bangladesh, India, and Pakistan). This study identified 474 young infants who had laboratory-confirmed RSV infection; additionally, this study tested specimens from 1,873 age and sex-matched healthy infants, which were found to be negative for RSV. The current age of that cohort is between 5 and 7 years, which provides a unique opportunity to gather information on the long-term effect of RSV infection in a large number of laboratory-confirmed cases at a low cost.

Given the relative frequency and impact of RSV infection in developing healthcare settings, should the investigators identify a high prevalence of subsequent wheeze and asthma the potential benefit of interventions to reduce RSV will be enhanced. In addition, this study will have the following supplementary benefits (1) the ability to report the feasibility to identify wheeze frequency by self-reporting in South Asian populations, (2) the feasibility and outcomes of tests that are utilized to support the diagnosis of asthma and other respiratory diseases in children, i.e. skin prick tests, Eosinophil count and spirometry.

Research Questions: The overarching aim of this study is to understand the long-term effect on child health of RSV infection occurring in the first two months of life. Therefore, through this study, the investigators aim to investigate the following research questions:

1. Is there an association between RSV infection in the first two months of life and development of asthma later in childhood?

2. Is the lung function of children who had RSV infection in the first 2 months of life lower than that of children who did not have RSV infection?

3. Is there an association between RSV infection in the first two months of life and physical development in childhood?

4. Are risk factors for childhood asthma different for the children who had RSV infection in the first two months of life than others without RSV infection at the same age?

Methodologies: The investigators have identified sites of the Aetiology of Neonatal Sepsis in South Asia (ANISA) study, two in Pakistan and one each in Bangladesh and India to implement this study. Health workers will visit the households of eligible children. Children whose parents provide consent will be visited three times in one year period, at baseline, after six months and the end of the year. In the first visit, a member of the research team will explain the study objectives and procedures to one of the family members (primarily the mother) of the eligible children to provide consent for enrolling the children in the study, the parents of the enrolled children will be interviewed using a structured questionnaire to record the current and previous health status of children. Study team members will remain blind about the RSV infectious status of the children to avoid enrollment bias. To ascertain asthma and wheeze, parents will be inquired about breathing difficulties of the children using a questionnaire designed by the International Study of Allergies and Asthma in Childhood (ISAAC), dermatitis will be defined by the criteria provided by The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. It was previously reported that terms such as ''wheeze'' and ''difficulty in breathing'' used in the ISAAC questionnaire have little validity when comparing clinical cases between parents and also between clinicians, and the conceptual understandings of ''wheeze'' for parents of children with reported wheeze are different from definitions used in epidemiology (Bisgaard & Szefler, 2007). To reduce the differences in patient responses, the research team will provide a video demonstration of wheeze and asthma-like symptoms to the parents before introducing the questionnaire. They will also introduce a child "case card" to the parents and request to record the wheezing episodes of their enrolled children using this case card. Additionally, they will also request the parents to reach team (over the phone) if they notice wheezing sound to their children, a research team will visit the symptomatic children and perform a physical assessment of the child using auscultation and peak flowmetry. The research team will return to the families after six months to emphasize the use of the case card for recording wheeze episodes and also refer the children to the health facilities for physical assessment (spirometry, exercise challenge test, skin prick test, and eosinophil count test and anthropometric measurements). In the health facilities, physicians will perform afore mention tests and procedures. The research team will return to the families again after one year of the first visit and collect the "case card" from where they will record the number of wheeze/asthma episode occurred in the last one year (follow-up period). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03876249
Study type Observational
Source Child Health Research Foundation, Bangladesh
Contact Samir K Saha, PhD
Phone 00880 2 9104211
Email samir@chrfbd.org
Status Not yet recruiting
Phase
Start date June 1, 2019
Completion date December 30, 2020

See also
  Status Clinical Trial Phase
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Recruiting NCT05734261 - Forced Oscillations Technique During a Metacholine Test in Children N/A
Recruiting NCT06044051 - Dynamics of the Upper and Lower Airway Respiratory Microbiomes Associated With Severe Infant Asthma N/A
Completed NCT04896502 - Effectiveness of Telemedicine Home Assessments for Identification and Reduction of Asthma Triggers N/A
Completed NCT03503812 - Mitigating the Health Effects of Desert Dust Storms Using Exposure-Reduction Approaches N/A
Recruiting NCT06003569 - Reducing Asthma Attacks in Disadvantaged School Children With Asthma N/A
Not yet recruiting NCT05902702 - Isotonic Saline for Children With Bronchiolitis N/A
Not yet recruiting NCT05547477 - Continuous EMG Measurements in Children With Asthma During Sleep
Completed NCT04388098 - Oral Health Status of Asthmatic Children
Terminated NCT03586544 - Reducing Exercise-induced Bronchoconstriction in Children With Asthma and Obesity Phase 4
Recruiting NCT04821908 - Consequences of COVID 19 Pandemic on Childhood Asthma
Not yet recruiting NCT03277170 - Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations Phase 2
Enrolling by invitation NCT06239844 - Navigating Together for Equitable Asthma Management for Children in Families Who Communicate in Language Other Than English N/A
Not yet recruiting NCT05974917 - Serious gaMes as Emerging E-health Interventions for Young People With neurologicaL or rEspiratory disoRders
Not yet recruiting NCT05997784 - Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing
Recruiting NCT05366309 - Performance and Adherence in Children Using Spacers N/A
Completed NCT05684926 - COVID-19 Pandemic Asthma Child Telerehabilitation Yoga N/A
Recruiting NCT04166344 - A mHealth Intervention to Improve Symptom Control in Children and Adolescents With Difficult-to-control Asthma N/A
Completed NCT05576142 - Oral Findings in Pediatric Patients With Allergic Rhinitis and/or Asthma
Completed NCT03907410 - The Tailored Adherence Incentives for Childhood Asthma Medications (TAICAM) Trial N/A